Tammy Mah-Fraser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tammy Mah-Fraser has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Yesim Demirci
Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
5 shared publications Michael B. Gorin
5 shared publicationsBrian W. Rigatti
4 shared publications- Daniel E. Weeks
Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
4 shared publications Robert E. Ferrell
Departments of 1Biostatistics and 2Human Genetics, Graduate School of Public Health, 3Department of Health Promotion and Development, School of Nursing, and 4UPMC Eye Center, Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh
4 shared publicationsAmy L. Radak
3 shared publications
Latest Publications
- Open Access
- 20 October 2024
- Published by University of Alberta Libraries in The International Review of Information Ethics
- Vol. 34 (1)
A Rossian Method for Applying Principles in AI
In the past several years there has been a rapid development of new technologies, applications, organizations, and institutions in the area of artificial intelligence (AI). At the same time, ethical reasoning about AI has not been able to keep up with the speed of these advances. As a result, developers are left to rely on existing rules, professional codes, policies and personal ethics which may not provide the appropriate guidance about ethical conduct and may require greater specificity (O'Leary). Many commentators have acknowledged the need for a clearer understanding of ethical values and principles to guide AI research. Drawing on insights from the formation of the field of biomedical ethics, we argue that AI ethics should make use of the method based on prima facie duties derived from W.D. Ross’ approach to ethics. A Rossian approach has proved influential in biomedical ethics. We further propose a modification to the list of principles proposed by Floridi and Cowls, arguing that the principles of explicability and accountability should be separated for ease of application. We argue that this method of applying principles is just what has been missing in AI ethics and is the crucial link between the now common lists of principles and putting them into practice in a way that can inform actual developments on the ground.
- 20 October 2024
- Published by University of Alberta Libraries in The International Review of Information Ethics
- Vol. 34 (1)
Open AccessA Rossian Method for Applying Principles in AI
In the past several years there has been a rapid development of new technologies, applications, organizations, and institutions in the area of artificial intelligence (AI). At the same time, ethical reasoning about AI has not been able to keep up with the speed of these advances. As a result, developers are left to rely on existing rules, professional codes, policies and personal ethics which may not provide the appropriate guidance about ethical conduct and may require greater specificity (O'Leary). Many commentators have acknowledged the need for a clearer understanding of ethical values and principles to guide AI research. Drawing on insights from the formation of the field of biomedical ethics, we argue that AI ethics should make use of the method based on prima facie duties derived from W.D. Ross’ approach to ethics. A Rossian approach has proved influential in biomedical ethics. We further propose a modification to the list of principles proposed by Floridi and Cowls, arguing that the principles of explicability and accountability should be separated for ease of application. We argue that this method of applying principles is just what has been missing in AI ethics and is the crucial link between the now common lists of principles and putting them into practice in a way that can inform actual developments on the ground.
- 21 March 2013
- Published by Springer Nature
- p. 113-118
Clinical Trial Complexity Measure – Balancing Constraints to Achieve Quality
- 21 March 2013
- Published by Springer Nature
- p. 113-118
Clinical Trial Complexity Measure – Balancing Constraints to Achieve Quality
- 1 January 2006
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 141 (1) , 208-210
A Novel RPGR Exon ORF15 Mutation in a Family With X-linked Retinitis Pigmentosa and Coats’-like Exudative Vasculopathy
- 1 January 2006
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 141 (1) , 208-210
A Novel RPGR Exon ORF15 Mutation in a Family With X-linked Retinitis Pigmentosa and Coats’-like Exudative Vasculopathy
- Top Cited Papers
- 1 September 2005
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 77 (3) , 389-407
Susceptibility Genes for Age-Related Maculopathy on Chromosome 10q26
- 1 September 2005
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 77 (3) , 389-407
Top Cited PapersSusceptibility Genes for Age-Related Maculopathy on Chromosome 10q26
- 1 February 2005
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 139 (2) , 386-388
Histopathologic study of X-linked cone-rod dystrophy (CORDX1) caused by a mutation in the RPGR exon ORF15
- 1 February 2005
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 139 (2) , 386-388
Histopathologic study of X-linked cone-rod dystrophy (CORDX1) caused by a mutation in the RPGR exon ORF15
- 1 September 2004
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 138 (3) , 504-505
A presumed missense mutation of RPGR causes abnormal RNA splicing with exon skipping
- 1 September 2004
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 138 (3) , 504-505
A presumed missense mutation of RPGR causes abnormal RNA splicing with exon skipping
- 1 July 2004
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 138 (1) , 171-173
A novel compound heterozygous mutation in the cellular retinaldehyde-binding protein gene (RLBP1) in a patient with retinitis punctata albescens
- 1 July 2004
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 138 (1) , 171-173
A novel compound heterozygous mutation in the cellular retinaldehyde-binding protein gene (RLBP1) in a patient with retinitis punctata albescens
- 1 November 2002
- Published by Wolters Kluwer Health in Cornea
- Vol. 21 (8) , 770-773
Fluorescein-Potentiated Argon Laser Therapy Improves Symptoms and Appearance of Corneal Neovascularization
To evaluate patients' self-assessment of their symptoms and cosmetic appearance after fluorescein-potentiated argon laser treatment (FPAL) for corneal inflammation associated with neovascularization. To describe the objective effects of FPAL therapy on established corneal neovascularization with secondary corneal edema and lipid keratopathy. Fifteen patients with corneal neovascularization resulting from various infectious and traumatic etiologies were enrolled in an open, nonrandomized pilot study. Treatment consisted of repeated sessions of intravenous fluorescein, a photosensitizer, combined with blue-green argon laser applications to abnormal corneal vessels. Patients completed a written survey to grade their symptoms and cosmetic appearance prior to treatment and at the end of the follow-up period. Objective changes in signs after FPAL treatment were described by two nonmasked ophthalmologists after slit-lamp examinations and review of serial corneal photographs. Clinical symptoms of blurred vision (p ≤ 0.003), photophobia (p ≤ 0.03), and cosmetic appearance (p ≤ 0.02) were found to be significantly improved by the patient's subjective assessment survey. There was a trend toward pain reduction (p ≤ 0.06) but no apparent reduction in tearing or foreign body sensation (p ≤ ns). Objective signs of corneal edema, neovascularization, and lipid keratopathy appeared to be reduced after FPAL therapy. FPAL therapy for corneal neovascularization, edema, and lipid keratopathy resulted in a significant reduction in symptoms and improved quality of life for 14 of 15 (93%) patients. A controlled clinical trial to confirm the reported improvement in signs observed in this pilot study should be considered.
- 1 November 2002
- Published by Wolters Kluwer Health in Cornea
- Vol. 21 (8) , 770-773
Fluorescein-Potentiated Argon Laser Therapy Improves Symptoms and Appearance of Corneal Neovascularization
To evaluate patients' self-assessment of their symptoms and cosmetic appearance after fluorescein-potentiated argon laser treatment (FPAL) for corneal inflammation associated with neovascularization. To describe the objective effects of FPAL therapy on established corneal neovascularization with secondary corneal edema and lipid keratopathy. Fifteen patients with corneal neovascularization resulting from various infectious and traumatic etiologies were enrolled in an open, nonrandomized pilot study. Treatment consisted of repeated sessions of intravenous fluorescein, a photosensitizer, combined with blue-green argon laser applications to abnormal corneal vessels. Patients completed a written survey to grade their symptoms and cosmetic appearance prior to treatment and at the end of the follow-up period. Objective changes in signs after FPAL treatment were described by two nonmasked ophthalmologists after slit-lamp examinations and review of serial corneal photographs. Clinical symptoms of blurred vision (p ≤ 0.003), photophobia (p ≤ 0.03), and cosmetic appearance (p ≤ 0.02) were found to be significantly improved by the patient's subjective assessment survey. There was a trend toward pain reduction (p ≤ 0.06) but no apparent reduction in tearing or foreign body sensation (p ≤ ns). Objective signs of corneal edema, neovascularization, and lipid keratopathy appeared to be reduced after FPAL therapy. FPAL therapy for corneal neovascularization, edema, and lipid keratopathy resulted in a significant reduction in symptoms and improved quality of life for 14 of 15 (93%) patients. A controlled clinical trial to confirm the reported improvement in signs observed in this pilot study should be considered.
- 1 April 2002
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 70 (4) , 1049-1053
X-Linked Cone-Rod Dystrophy (Locus COD1): Identification of Mutations in RPGR Exon ORF15
- 1 April 2002
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 70 (4) , 1049-1053
X-Linked Cone-Rod Dystrophy (Locus COD1): Identification of Mutations in RPGR Exon ORF15
- 1 January 2002
- Published by Swets & Zeitlinger Publishers in Ophthalmic Genetics
- Vol. 23 (4) , 209-223
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy
Age-related maculopathy (ARM) is a multifactorial disorder known to have a substantial genetic component. The epsilon4 allele of the apolipoprotein E gene (APOE-4) has previously been reported to have a protective effect on ARM risk, while the APOE-2 allele may increase disease risk. This study combined four independent data sets (three US and one European) of Caucasian ARM patients and controls in order to obtain better statistical power to examine the role of APOE in ARM. APOE genotype and allele frequencies were compared for 617 ARM cases and 1260 controls, adjusting for age and sex differences between the two groups via multiple logistic regression. The protective effect of the APOE-4 allele on ARM risk was confirmed (age- and sex-adjusted odds ratio (OR) for APOE-4 carriers 0.54, 95% confidence interval (CI) 0.41-0.70, p < 0.0001). The effect of APOE-4 did not differ significantly between males and females and was observed consistently for both atrophic and neovascular ARM. Evidence for an increased risk of ARM due to the APOE-2 allele was found for men, but not for women (OR for men 1.54, 95% CI 0.97-2.45; OR for women 0.74, 95% CI 0.52-1.06, p = 0.01 for interaction of sex and APOE-2 carrier status). These data confirm that the APOE-4 allele, or an allele in linkage disequilibrium with it, reduces the risk of ARM. They also suggest that the effect of the APOE-2 allele may vary by gender, and that APOE-2 may confer an increased risk only to males.
- 1 January 2002
- Published by Swets & Zeitlinger Publishers in Ophthalmic Genetics
- Vol. 23 (4) , 209-223
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy
Age-related maculopathy (ARM) is a multifactorial disorder known to have a substantial genetic component. The epsilon4 allele of the apolipoprotein E gene (APOE-4) has previously been reported to have a protective effect on ARM risk, while the APOE-2 allele may increase disease risk. This study combined four independent data sets (three US and one European) of Caucasian ARM patients and controls in order to obtain better statistical power to examine the role of APOE in ARM. APOE genotype and allele frequencies were compared for 617 ARM cases and 1260 controls, adjusting for age and sex differences between the two groups via multiple logistic regression. The protective effect of the APOE-4 allele on ARM risk was confirmed (age- and sex-adjusted odds ratio (OR) for APOE-4 carriers 0.54, 95% confidence interval (CI) 0.41-0.70, p < 0.0001). The effect of APOE-4 did not differ significantly between males and females and was observed consistently for both atrophic and neovascular ARM. Evidence for an increased risk of ARM due to the APOE-2 allele was found for men, but not for women (OR for men 1.54, 95% CI 0.97-2.45; OR for women 0.74, 95% CI 0.52-1.06, p = 0.01 for interaction of sex and APOE-2 carrier status). These data confirm that the APOE-4 allele, or an allele in linkage disequilibrium with it, reduces the risk of ARM. They also suggest that the effect of the APOE-2 allele may vary by gender, and that APOE-2 may confer an increased risk only to males.